Provider Connections: Dr. Yi Lin on Cell Therapy Treatments in Lymphoid Malignancies

Special thanks to Goldman Philanthropic Partnerships for funding this series.

00:00 - Introduction to CAR-T Therapy
00:39 - FDA-Approved Indications
01:54 - How CAR-T Cells are Made
03:07 - The Treatment Process and Side Effects
04:30 - The Efficacy of CAR-T Therapy
05:17 - The Patient Journey and Logistics
08:21 - Unprecedented Clinical Response
08:52 - Conclusion and Acknowledgments

Descriptions:
00:00 - Introduction to CAR-T Therapy
Introduction to Dr. Yi Lin, Medical Director of the Mayo Clinic's cell therapy program and CAR-T (chimeric antigen receptor T-cell) therapy as a transformative immunotherapy for lymphoma patients.
00:39 - FDA-Approved Indications
Various types of lymphoma for which CAR-T therapy is FDA-approved. These include aggressive non-Hodgkin lymphomas like diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), as well as indolent lymphomas such as follicular lymphoma (FL).
01:54 - How CAR-T Cells are Made
CAR-T cells are created from a patient's own T-cells, making it a highly personalized treatment. The patient's white blood cells are collected and sent to a lab, where they are genetically modified to become CAR-T cells.
03:07 - The Treatment Process and Side Effects
Before the CAR-T cells are infused, patients receive chemotherapy to prepare their immune system. This allows the new CAR-T cells to multiply and become active. Unique side effects can occur, such as cytokine release syndrome and neurologic changes, which are closely monitored by specialists at the treatment center for about a month after infusion.
04:30 - The Efficacy of CAR-T Therapy
Emphasis on the unprecedented clinical response rates and the potential for a long-lasting, durable remission, and even a cure for many patients.
05:17 - The Patient Journey and Logistics
Outlines of the typical patient journey. It begins with a referral to a specialized CAR-T treatment center for evaluation. Patients then undergo a procedure called leukapheresis to collect their white blood cells. After the CAR-T cells are manufactured, the patient returns for the infusion.
08:21 - Unprecedented Clinical Response
The significant impact of CAR-T therapy, ability to offer durable remission and a cure for many patients with relapsed refractory lymphoma.
08:52 - Conclusion and Acknowledgments
The video concludes with a thank you to the patients, the Mayo Clinic team, and the Goldman Philanthropic Partnerships for their generous support in creating this educational series.

Visit Mayo Clinic: https://mayocl.in/2COVmlm

Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/
Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/
Follow Mayo Clinic on X, formerly Twitter: https://x.com/MayoClinic
Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic